LivaNova (LIVN) – Analysts’ Weekly Ratings Updates

A number of research firms have changed their ratings and price targets for LivaNova (NASDAQ: LIVN):

• 2/27/2026 – LivaNova had its price target raised by Barclays PLC from $67.00 to $73.00. They now have an “equal weight” rating on the stock.
• 2/25/2026 – LivaNova was given a new $80.00 price target by Stifel Nicolaus.
• 2/25/2026 – LivaNova had its price target raised by Needham & Company LLC from $64.00 to $81.00. They now have a “buy” rating on the stock.
• 2/19/2026 – LivaNova had its “overweight” rating reaffirmed by Piper Sandler. They now have a $85.00 price target on the stock.
• 1/9/2026 – LivaNova had its price target raised by Barclays PLC from $58.00 to $67.00. They now have an “equal weight” rating on the stock.
• 1/9/2026 – LivaNova had its “neutral” rating reaffirmed by The Goldman Sachs Group, Inc.. They now have a $66.00 price target on the stock.

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.